Healthcare IT News June 14, 2019
The largest U.S.-based genetics study – 500,000 samples drawn from Intermountain Health’s patient population – aims to improve precision medicine.
Some of the most common illnesses health systems face like heart disease or cancer can be managed, caught or outright prevented if a provider has the proper insights into a patient’s genome.
WHAT HAPPENED
This is the promise of a new massive clinical DNA study, pairing 500,000 samples drawn from Intermountain Health’s patient population and analyzing them by deCODE, a subsidiary of Amgen based in Reykjavik, Iceland.
Understanding and screening for hereditary diseases like breast and colon cancer and heart disease, to name a few, requires deep insights into the DNA of a massive patient population. The new collaborative study...
Today's Sponsors
Today's Sponsor